TScan Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update
Announced strategic reorganization to focus on in vivo-engineered TCR-T cell therapy for solid tumorsAdvancing PRAME- and MAGE-A4-targeted in vivo TCR-T candidates for solid tumors through IND-enabling studies; on track to dose first patient in Q4 2027Paused further enrollment in Phase 3 ALLOHA-2™…